Many approved prescriptions are never filled, with fill rates dropping sharply when out-of-pocket costs exceed $175.

Second study shows that individuals exposed to GLP-1 RAs have significantly higher prevalence rates of hair and scalp involvement.

The Food and Drug Administration (FDA) has approved Weltruza ™ (olanzapine) as the first once-monthly subcutaneous long-acting injectable (LAI) for the treatment of schizophreni ...

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

A review of notable updates that occurred in September 2026 for investigational products in development.

Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...

Key insights from Fall Clinical 2026 on diagnosing and managing inflammatory skin conditions and post-inflammatory dyspigmentation in patients with skin of color.

Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.

Key takeaways from the 26th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada were published.

Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.

Findings seen among pediatric patients presenting to the emergency department with moderate-to-severe acute pain ...